



You are cordially invited to attend a **STIVARGA® (regorafenib)** promotional non-CME presentation:
Therapy for Patients with Previously Treated Metastatic Colorectal Cancer (mCRC): Your Patient's Journey

INDICATION

STIVARGA is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.

Join your colleagues to learn more about:

- ☐ Current National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines®) describing therapies for patients with mCRC
- ☐ How STIVARGA works as an oral inhibitor of multiple kinases
- ☐ The clinical trial results of STIVARGA for previously treated patients with mCRC
- ☐ Dosing strategies for certain treatment-emergent adverse events, including dose modifications and temporary or permanent discontinuations
- ☐ Bayer's support programs including financial and nursing services for offices and patients

Date: October 28, 2020

Time: 6:00 PM Pacific

Venue: Virtual Meeting

Address: **Virtual Meeting URL:**
<https://tallenevents.webex.com/tallenevents/onstage/g.php?MTID=ede51b3366c4a444c1f359a28e2895136>

For technical assistance the day of the event please call: 732-969-5000 Ext. 157

Program #: BAY0000822

Bayer Presenter: Timothy Freitas, MS, RN, PhD

ONE or Sales Consultant Info: Timothy Freitas
TIMOTHY.FREITAS@BAYER.COM
412-526-7193

If you would like to attend, please RSVP at <https://tallenevents.webex.com/tallenevents/onstage/g.php?MTID=ede51b3366c4a444c1f359a28e2895136> or contact the Bayer Speaker Bureau Registration Team at 866-914-9071 or RSVPBayersb@connectPW.com

This program is not affiliated with or endorsed by the Physician Network.

Portions of this program may be reportable under the Payment to Physicians Sunshine Act. All medical professionals are welcome, MD, RN, PharmD, etc; however, we cannot accommodate any non-medical professionals, such as spouses or guests.

IMPORTANT SAFETY INFORMATION

WARNING: HEPATOTOXICITY

- Severe and sometimes fatal hepatotoxicity has occurred in clinical trials.
- Monitor hepatic function prior to and during treatment.
- Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.

Hepatotoxicity: Severe drug-induced liver injury with fatal outcome occurred in STIVARGA-treated patients across all clinical trials. In most cases, liver dysfunction occurred within the first 2 months of therapy and was characterized by a hepatocellular pattern of injury. In mCRC, fatal hepatic failure occurred in 1.6% of patients in the STIVARGA arm and in 0.4% of patients in the placebo arm.

Liver Function Monitoring: Obtain liver function tests (ALT, AST, and bilirubin) before initiation of STIVARGA and monitor at least every 2 weeks during the first 2 months of treatment. Thereafter, monitor monthly or more frequently as clinically indicated. Monitor liver function tests weekly in patients experiencing elevated liver function tests until improvement to less than 3 times the upper limit of normal (ULN) or baseline values. Temporarily hold and then reduce or permanently discontinue STIVARGA, depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis.

Please see additional Important Safety Information on the next page. For important risk and use information, please [click here](#) for the full Prescribing Information.

IMPORTANT SAFETY INFORMATION (continued)

Infections: STIVARGA caused an increased risk of infections. The overall incidence of infection (Grades 1-5) was higher (32% vs 17%) in 1142 STIVARGA-treated patients as compared to the control arm in randomized placebo-controlled trials. The incidence of Grade 3 or greater infections in STIVARGA-treated patients was 9%. The most common infections were urinary tract infections (5.7%), nasopharyngitis (4.0%), mucocutaneous and systemic fungal infections (3.3%) and pneumonia (2.6%). Fatal outcomes caused by infection occurred more often in patients treated with STIVARGA (1.0%) as compared to patients receiving placebo (0.3%); the most common fatal infections were respiratory (0.6% vs 0.2%). Withhold STIVARGA for Grade 3 or 4 infections, or worsening infection of any grade. Resume STIVARGA at the same dose following resolution of infection.

Hemorrhage: STIVARGA caused an increased incidence of hemorrhage. The overall incidence (Grades 1-5) was 18.2% in 1142 patients treated with STIVARGA vs 9.5% with placebo in randomized, placebo-controlled trials. The incidence of Grade 3 or greater hemorrhage in patients treated with STIVARGA was 3.0%. The incidence of fatal hemorrhagic events was 0.7%, involving the central nervous system or the respiratory, gastrointestinal, or genitourinary tracts. Permanently discontinue STIVARGA in patients with severe or life-threatening hemorrhage and monitor INR levels more frequently in patients receiving warfarin.

Gastrointestinal Perforation or Fistula: Gastrointestinal perforation occurred in 0.6% of 4518 patients treated with STIVARGA across all clinical trials of STIVARGA administered as a single agent; this included eight fatal events. Gastrointestinal fistula occurred in 0.8% of patients treated with STIVARGA and in 0.2% of patients in the placebo arm across randomized, placebo-controlled trials. Permanently discontinue STIVARGA in patients who develop gastrointestinal perforation or fistula.

Dermatological Toxicity: In randomized, placebo-controlled trials, adverse skin reactions occurred in 71.9% of patients with STIVARGA arm and 25.5% of patients in the placebo arm including hand-foot skin reaction (HFSR) also known as palmar-plantar erythrodysesthesia syndrome (PPES) and severe rash, requiring dose modification. In the randomized, placebo-controlled trials, the overall incidence of HFSR was higher in 1142 STIVARGA-treated patients (53% vs 8%) than in the placebo-treated patients. Most cases of HFSR in STIVARGA-treated patients appeared during the first cycle of treatment. The incidences of Grade 3 HFSR (16% vs <1%), Grade 3 rash (3% vs <1%), serious adverse reactions of erythema multiforme (<0.1% vs 0%), and Stevens-Johnson syndrome (<0.1% vs 0%) were higher in STIVARGA-treated patients. Across all trials, a higher incidence of HFSR was observed in Asian patients treated with STIVARGA (all grades: 72%; Grade 3: 18%). Toxic epidermal necrolysis occurred in 0.02% of 4518 STIVARGA-treated patients across all clinical trials of STIVARGA administered as a single agent. Withhold STIVARGA, reduce the dose, or permanently discontinue depending on the severity and persistence of dermatologic toxicity.

Hypertension: Hypertensive crisis occurred in 0.2% in STIVARGA-treated patients and in none of the patients in placebo arm across all randomized, placebo-controlled trials. STIVARGA caused an increased incidence of hypertension (30% vs 8% in mCRC). The onset of hypertension occurred during the first cycle of treatment in most patients who developed hypertension (67% in randomized, placebo controlled trials). Do not initiate STIVARGA until blood pressure is adequately controlled. Monitor blood pressure weekly for the first 6 weeks of treatment and then every cycle, or more frequently, as clinically indicated. Temporarily or permanently withhold STIVARGA for severe or uncontrolled hypertension.

Cardiac Ischemia and Infarction: STIVARGA increased the incidence of myocardial ischemia and infarction (0.9% with STIVARGA vs 0.2% with placebo) in randomized placebo-controlled trials. Withhold STIVARGA in patients who develop new or acute cardiac ischemia or infarction, and resume only after resolution of acute cardiac ischemic events if the potential benefits outweigh the risks of further cardiac ischemia.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one of 4800 STIVARGA-treated patients across all clinical trials. Perform an evaluation for RPLS in any patient presenting with seizures, severe headache, visual disturbances, confusion, or altered mental function. Discontinue STIVARGA in patients who develop RPLS.

Wound Healing Complications: Impaired wound healing complications can occur in patients who receive drugs that inhibit the VEGF signaling pathway. Therefore, STIVARGA has the potential to adversely affect wound healing. Withhold STIVARGA for at least 2 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of STIVARGA after resolution of wound healing complications has not been established.

Embryo-fetal Toxicity: STIVARGA can cause fetal harm when administered to a pregnant woman. There are no available data on STIVARGA use in pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with STIVARGA and for 2 months after the final dose.

Nursing Mothers: Because of the potential for serious adverse reactions in breastfed infants from STIVARGA, do not breastfeed during treatment with STIVARGA and for 2 weeks after the final dose.

Most Frequently Observed Adverse Drug Reactions in mCRC (≥30%): The most frequently observed adverse drug reactions (≥30%) in STIVARGA-treated patients vs placebo-treated patients in mCRC, respectively, were: asthenia/fatigue (64% vs 46%), pain (59% vs 48%), decreased appetite and food intake (47% vs 28%), HFSR/PPE (45% vs 7%), diarrhea (43% vs 17%), mucositis (33% vs 5%), weight loss (32% vs 10%), infection (31% vs 17%), hypertension (30% vs 8%), and dysphonia (30% vs 6%).

Please see additional Important Safety Information on the next page. For important risk and use information, please [click here](#) for the full Prescribing Information.

Certain HCPs and other individuals may be prohibited from participating in this event based on additional state and federal laws that restrict meals and gifts. Bayer HealthCare requests that you please comply with any and all laws in the state where you hold a license.

Vermont Attendees: If you are a Vermont-licensed HCP, you may attend a Speaker Program, but you must not accept a meal.

Veterans Affairs/Executive Officers/Federal Employee Attendees: If you are an employee of the Department of Veterans Affairs or of the federal government (even part-time), you may attend a Speaker Program but you will be responsible for your meal.

Minnesota Attendees: If you are a Minnesota-licensed practitioner, you may attend a Speaker Program; however, you may not accept a gift/meal.

Bayer complies with all State, Federal, and Global disclosure requirements.



©2020 Bayer. All rights reserved.
100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981-0915 USA
Bayer, the Bayer Cross and STIVARGA are registered trademarks of Bayer.
PP-STI-US-1005-1 03/20


Stivarga[®]
(regorafenib) tablets